The Phenomenon of PSA Bounce After Radiation Therapy



Following radiotherapy for prostate cancer, the serum PSA level will fall to reach a nadir several years later. PSA bounce refers to a benign intermittent PSA rise prior to subsequent decrease. It has been observed in all forms of primary radiotherapy strategies, most recently in stereotactic radiation where it was noted in 29 % of patients. Comparison of published data is difficult due to variations in definitions, populations studied, and types of treatment. The majority of studies, however, do not reveal a relationship between PSA bounce and biochemical control. The only consistent pretreatment factor that appears to predict for PSA bounce is patient age at treatment. The updated ASTRO definition of biochemical failure following radiotherapy treatment (PSA nadir plus 2 ng/mL) aims to reduce the false-positive rate due to bounce but is not foolproof as bounces will still occur above this value. Pre-intervention counseling and judicious timing and frequency of PSA-testing posttreatment may help relieve the anxieties associated with PSA bounce.


  1. 1.
    Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53(5):1097–105.PubMedCrossRefGoogle Scholar
  2. 2.
    Wallner KE, Blasko J, Dattoli MJ. Evaluating cancer status. In: Wallner KE, Blasko J, Dattoli MJ, editors. Prostate brachytherapy made complicated. Seattle: SmartMedicine Publishing; 1997. p. 11–4.Google Scholar
  3. 3.
    King CR, Brooks JD, Gill H, Pawlicki T, Cotrutz C, Presti Jr JC. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys. 2009;73(4):1043–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Rosser CJ, Kuban DA, Levy LB, et al. Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer. J Urol. 2002;168(5):2001–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Hanlon AL, Pinover WH, Horwitz EM, Hanks GE. Patterns and fate of PSA bouncing following 3D-CRT. Int J Radiat Oncol Biol Phys. 2001;50(4):845–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Horwitz EM, Levy LB, Thames HD, et al. Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: a multi-institutional pooled analysis. Cancer. 2006;107(7):1496–502.PubMedCrossRefGoogle Scholar
  7. 7.
    Sheinbein C, Teh BS, Mai WY, Grant W, Paulino A, Butler EB. Prostate-specific antigen bounce after intensity-modulated radiotherapy for prostate cancer. Urology. 2010;76(3):728–33.PubMedCrossRefGoogle Scholar
  8. 8.
    Pickles T. Prostate-specific antigen (PSA) bounce and other fluctuations: which biochemical relapse definition is least prone to PSA false calls? An analysis of 2030 men treated for prostate cancer with external beam or brachytherapy with or without adjuvant androgen deprivation therapy. Int J Radiat Oncol Biol Phys. 2006;64(5):1355–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Crook J, Gillan C, Yeung I, Austen L, McLean M, Lockwood G. PSA kinetics and PSA bounce following permanent seed prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2007;69(2):426–33.PubMedCrossRefGoogle Scholar
  10. 10.
    Mitchell DM, Swindell R, Elliott T, Wylie JP, Taylor CM, Logue JP. Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancer. Radiother Oncol. 2008;88(1):102–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Bostancic C, Merrick GS, Butler WM, et al. Isotope and patient age predict for PSA spikes after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2007;68(5):1431–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Patel C, Elshaikh MA, Angermeier K, et al. PSA bounce predicts early success in patients with permanent iodine-125 prostate implant. Urology. 2004;63(1):110–3.PubMedCrossRefGoogle Scholar
  13. 13.
    Ciezki JP, Reddy CA, Garcia J, et al. PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time. Int J Radiat Oncol Biol Phys. 2006;64(2):512–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Critz FA, Williams WH, Levinson AK, et al. Prostate specific antigen bounce after simultaneous irradiation for prostate cancer: the relationship to patient age. J Urol. 2003;170(5):1864–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Stock RG, Stone NN, Cesaretti JA. Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications. Int J Radiat Oncol Biol Phys. 2003;56(2):448–53.PubMedCrossRefGoogle Scholar
  16. 16.
    Das P, Chen MH, Valentine K, et al. Using the magnitude of PSA bounce after MRI-guided prostate brachytherapy to distinguish recurrence, benign precipitating factors, and idiopathic bounce. Int J Radiat Oncol Biol Phys. 2002;54(3):698–702.PubMedCrossRefGoogle Scholar
  17. 17.
    Merrick GS, Butler WM, Wallner KE, Galbreath RW, Anderson RL. Prostate-specific antigen spikes after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2002;54(2):450–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Critz FA, Williams WH, Benton JB, Levinson AK, Holladay CT, Holladay DA. Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. J Urol. 2000;163(4):1085–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Crook J, Malone S, Perry G, Bahadur Y, Robertson S, Abdolell M. Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. Int J Radiat Oncol Biol Phys. 2000;48(2):355–67.PubMedCrossRefGoogle Scholar
  20. 20.
    Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys. 1997;37(5):1035–41.Google Scholar
  21. 21.
    Roach III M, Hanks G, Thames Jr H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65(4):965–74.PubMedCrossRefGoogle Scholar
  22. 22.
    Prestigiacomo AF, Stamey TA. Physiological variation of serum prostate specific antigen in the 4.0 to 10.0 ng/ml. range in male volunteers. J Urol. 1996;155(6):1977–80.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  1. 1.Department of UrologySouthend University Hospital NHS Foundation TrustWestcliff-on-Sea, EssexUK
  2. 2.Department of Urology, Urology CentreGuy’s and St. Thomas’ HospitalsLondonUK

Personalised recommendations